People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

Researchers Identify a Potential Biomarker of Parkinson's Disease Progression Nov. 12 ... are detected in blood once symptoms have started in Lewy's body diseases, ... July 23, 2024 ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

Patients living with Parkinson’s disease are encouraged to engage in regular exercise to help manage symptoms and improve ...

A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

Making compounds that halt or reverse the progression of Parkinson's disease is especially challenging because the field is ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...

Researchers Identify a Potential Biomarker of Parkinson's Disease Progression Nov. 12 ... provide continual and improved treatment for the symptoms of Parkinson's disease (PD) ...

AstraZeneca’s diabetes drug Bydureon (exenatide) has failed to slow the progression of Parkinson’s disease motor symptoms in a Phase III trial. The University College London (UCL) in the UK ...